Search
APD668
go.drugbank.com/drugs/DB05166ExperimentalAPD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also av...
Vanillyl butyl ether
go.drugbank.com/drugs/DB11299ApprovedIt is added to food products as a flavoring agent. … It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.
Products: Cell Acher Sports Body MassageTaurocholic acid
go.drugbank.com/drugs/DB04348ApprovedIt acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.
Maduramicin
go.drugbank.com/drugs/DB11525ExperimentalVet approvedMaduramicin is an antiprotozoal agent used in veterinary medicine as prophylaxis against coccidiosis. … It is a naturally occurring compound which was first isolated from the actinomycete, Actinomadura rubra.
Chenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalChenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production...
Tromethamine
go.drugbank.com/drugs/DB03754ApprovedInvestigationalas an alkalizer. … It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used
AICA ribonucleotide
go.drugbank.com/drugs/DB01700InvestigationalThe drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity … AICAR has been used clinically to treat and protect against cardiac ischemic injury.
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.
Bimoclomol
go.drugbank.com/drugs/DB06258ExperimentalBimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.